Therefore, clinical treatment that targets AP-2α expression in the context of the MSI-positive HNSCC tumor would potentially deter tumor proliferation (ie. via PTEN and RASSF1A reexpression) and resolve genomic instability (ie. via MLH1 reexpression). Here, PTEN is linked to neoplasm.